Overview

ALK33-001: A Study of RDC-0313 Administered to Healthy Adults

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of RDC-0313 following oral administration.
Phase:
Phase 1
Details
Lead Sponsor:
Alkermes, Inc.
Treatments:
ALKS-33